Linked Life Data

12888182

Source:http://linkedlifedata.com/resource/pubmed/id/12888182

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2003-7-30
pubmed:abstractText
S100B is a protein which exerts both detrimental and neurotrophic effects, depending on its concentration in brain tissue. An increase of S100B in micromolar concentrations is observed in traumatic brain conditions and is associated with poor outcome. Micromolar levels of extracellular S100B in vitro may have deleterious effects. However, in nanomolar concentrations S100B has multiple neurotrophic effects in vitro may in vivo be regarded as a hallmark of neuroprotective efforts. This pilot study addresses the hypothesis that S100B serum concentrations may be of predictive validity for the response to antidepressant treatment in patients with major depression. S100B plasma levels were determined in 25 patients with major depression and 25 matched healthy controls using an immunofluorimetric sandwich assay. S100B plasma levels were significantly higher in major depressive patients than in healthy controls and positively correlated with treatment response after 4 weeks of treatment. In a linear regression model, a significant predictive effect was found only for S100B and severity of depressive symptoms upon admission. These results suggest that neuroprotective functions of S100B counterbalance neurodegenerative mechanisms that are involved in the pathophysiology of major depression and in the response to antidepressant treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0924-977X
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
235-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12888182-Adult, pubmed-meshheading:12888182-Antidepressive Agents, pubmed-meshheading:12888182-Case-Control Studies, pubmed-meshheading:12888182-Depressive Disorder, Major, pubmed-meshheading:12888182-Diagnostic and Statistical Manual of Mental Disorders, pubmed-meshheading:12888182-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:12888182-Female, pubmed-meshheading:12888182-Humans, pubmed-meshheading:12888182-Linear Models, pubmed-meshheading:12888182-Male, pubmed-meshheading:12888182-Mental Status Schedule, pubmed-meshheading:12888182-Middle Aged, pubmed-meshheading:12888182-Nerve Growth Factors, pubmed-meshheading:12888182-Pilot Projects, pubmed-meshheading:12888182-Predictive Value of Tests, pubmed-meshheading:12888182-Reproducibility of Results, pubmed-meshheading:12888182-S100 Proteins
pubmed:year
2003
pubmed:articleTitle
S100B and response to treatment in major depression: a pilot study.
pubmed:affiliation
Department of Psychiatry, University of Muenster, Albert-Schweitzer-Strasse 11, D-48129 Muenster, Germany. arolt@uni-muenster.de
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial